Pancreatic adenocarcinoma continues to be one of the most difficult cancers to treat. New therapies are urgently needed for the majority of patients with this disease. Murine studies employing tumor cells genetically- modified to express cytokines have demonstrated the induction of potent immunity that can cure mice of preestablished tumors. Experiments aimed at dissecting the mechanism of this response have revealed that both CD8+ and CD4+ T cells are critical effectors of the systemic immunity generated. These studies have led to ongoing clinical trials that are testing this approach for the treatment of patients with cancer. Although the specificity of the immune response seen in these models suggests that unique antigens are being expressed by the tumor and recognized by the ensuing immune response, in most cases the identity of these antigens is unknown. Recently, the identification of several murine and human melanoma antigens has validated these earlier hypotheses, and has provided a strong impetus for the identification of other human tumor antigens that can be exploited therapeutically. Antigen identification requires methods for generating T cell lines and clones, and for isolating either the gene encoding the tumor antigen or the antigen itself. We have developed methods for routinely generating tumor-specific CD8+ and CD4+ T cells from lymphocytes isolated from vaccinated patients. However, current antigen isolation technologies only allow the routine identification of Major Histocompatibility Complex (MHC) class I-restricted antigens. There is evidence to suggest that at least some MHC class I and II-restricted tumor- specific antigenic epitopes may derive from the same cellular protein. In addition, pre-clinical models evaluating recombinant antigen-specific vaccine strategies have demonstrated priming of potent antitumor immunity when the product of a gene encoding for a single tumor-specific antigen is delivered to both the MHC class I and II antigen-processing pathways. Drawing on our previous experience with antigen identification, we will identify tumor antigens expressed by human pancreatic adenocarcinomas. Both CD8+ and CD4+ pancreatic tumor-specific T cell lines and clones will be generated from lymphocytes isolated from patients with adenocarcinoma of the pancreas following vaccination with a GM-CSF secreting pancreatic tumor vaccine. A genetic approach will be used to identify genes encoding for MHC class I-restricted antigens. The identified antigens will be evaluated for recognition by CD4+ T cell lines and clones. Ultimately, the identification of common pancreatic antigens will allow the development of generalized gene therapy vaccine approaches that can generate immune responses potent enough to treat adenocarcinoma of the pancreas.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA062924-04
Application #
6237458
Study Section
Project Start
1997-02-28
Project End
1997-12-31
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
4
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Al Efishat, Mohammad A; Attiyeh, Marc A; Eaton, Anne A et al. (2018) Multi-institutional Validation Study of Pancreatic Cyst Fluid Protein Analysis for Prediction of High-risk Intraductal Papillary Mucinous Neoplasms of the Pancreas. Ann Surg 268:340-347
Cruz-Correa, Marcia; Hylind, Linda M; Marrero, Jessica Hernandez et al. (2018) Efficacy and Safety of Curcumin in Treatment of Intestinal Adenomas in Patients With Familial Adenomatous Polyposis. Gastroenterology 155:668-673
Christmas, Brian J; Rafie, Christine I; Hopkins, Alexander C et al. (2018) Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs. Cancer Immunol Res 6:1561-1577
Blair, Alex B; Murphy, Adrian (2018) Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future. Curr Probl Cancer 42:49-58
Raman, Aadhithya; Lennon, Anne Marie (2018) Cyst Fluid Biomarkers - Diagnosis and Prediction of Malignancy for Cystic Lesions of the Pancreas. Visc Med 34:178-181
Noë, Michaël; Pea, Antonio; Luchini, Claudio et al. (2018) Whole-exome sequencing of duodenal neuroendocrine tumors in patients with neurofibromatosis type 1. Mod Pathol 31:1532-1538
Cohen, Joshua D; Li, Lu; Wang, Yuxuan et al. (2018) Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359:926-930
Shumar, Stephanie A; Kerr, Evan W; Geldenhuys, Werner J et al. (2018) Nudt19 is a renal CoA diphosphohydrolase with biochemical and regulatory properties that are distinct from the hepatic Nudt7 isoform. J Biol Chem 293:4134-4148
Li, Yuguo; Qiao, Yuan; Chen, Hanwei et al. (2018) Characterization of tumor vascular permeability using natural dextrans and CEST MRI. Magn Reson Med 79:1001-1009
Saung, May Tun; Muth, Stephen; Ding, Ding et al. (2018) Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer. J Immunother Cancer 6:118

Showing the most recent 10 out of 883 publications